Stock Track | Junshi Biosciences Soars 5.11% Intraday on Positive Clinical Data and Broker Upgrade

Stock Track04-20 09:45

Junshi Biosciences' stock surged 5.11% during intraday trading on Monday, extending its recent positive momentum in the market.

The movement appears driven by multiple catalysts, including the disclosure of key clinical data at the ongoing American Association for Cancer Research (AACR) annual meeting. The company presented data for two flagship pipeline candidates: JS207 (a PD-1/VEGF bispecific antibody) and JS212 (an EGFR/HER3 ADC), with plans to advance both toward pivotal registration trials within the year.

Additional support came from Pacific Securities raising its target price for Junshi Biosciences to RMB 53.12 with a "Buy" rating. The company also reported full-year revenue growth of 28.23%, with core product Toripalimab achieving over 40% sales growth, and the expiration without execution of its third-largest shareholder's share reduction plan, removing a potential overhang.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144238673?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-20 09:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144238673","market":"hk","top_or_hot":-1,"title":"Stock Track | Junshi Biosciences Soars 5.11% Intraday on Positive Clinical Data and Broker Upgrade","media":"Stock Track","content":"<p>Junshi Biosciences' stock surged 5.11% during intraday trading on Monday, extending its recent positive momentum in the market.</p><p>The movement appears driven by multiple catalysts, including the disclosure of key clinical data at the ongoing American Association for Cancer Research (AACR) annual meeting. The company presented data for two flagship pipeline candidates: JS207 (a PD-1/VEGF bispecific antibody) and JS212 (an EGFR/HER3 ADC), with plans to advance both toward pivotal registration trials within the year.</p><p>Additional support came from Pacific Securities raising its target price for Junshi Biosciences to RMB 53.12 with a \"Buy\" rating. The company also reported full-year revenue growth of 28.23%, with core product Toripalimab achieving over 40% sales growth, and the expiration without execution of its third-largest shareholder's share reduction plan, removing a potential overhang.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Junshi Biosciences Soars 5.11% Intraday on Positive Clinical Data and Broker Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Junshi Biosciences Soars 5.11% Intraday on Positive Clinical Data and Broker Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-20 09:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Junshi Biosciences' stock surged 5.11% during intraday trading on Monday, extending its recent positive momentum in the market.</p><p>The movement appears driven by multiple catalysts, including the disclosure of key clinical data at the ongoing American Association for Cancer Research (AACR) annual meeting. The company presented data for two flagship pipeline candidates: JS207 (a PD-1/VEGF bispecific antibody) and JS212 (an EGFR/HER3 ADC), with plans to advance both toward pivotal registration trials within the year.</p><p>Additional support came from Pacific Securities raising its target price for Junshi Biosciences to RMB 53.12 with a \"Buy\" rating. The company also reported full-year revenue growth of 28.23%, with core product Toripalimab achieving over 40% sales growth, and the expiration without execution of its third-largest shareholder's share reduction plan, removing a potential overhang.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1144238673","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144238673","pubTimestamp":1776649529,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Junshi Biosciences' stock surged 5.11% during intraday trading on Monday, extending its recent positive momentum in the market.The movement appears driven by multiple catalysts, including the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"个股赛道|君实生物盘中大涨5.11%临床数据利好券商升级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Junshi Biosciences' stock surged 5.11% during intraday trading on Monday, extending its recent positive momentum in the market.The movement appears driven by multiple catalysts, including the disclosure of key clinical data at the ongoing American Association for Cancer Research (AACR) annual meeting. The company presented data for two flagship pipeline candidates: JS207 (a PD-1/VEGF bispecific antibody) and JS212 (an EGFR/HER3 ADC), with plans to advance both toward pivotal registration trials within the year.Additional support came from Pacific Securities raising its target price for Junshi Biosciences to RMB 53.12 with a \"Buy\" rating. The company also reported full-year revenue growth of 28.23%, with core product Toripalimab achieving over 40% sales growth, and the expiration without execution of its third-largest shareholder's share reduction plan, removing a potential overhang.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144238673","isCrawlerRequest":true}